← Back to Search

Cholinesterase Inhibitor

Echothiophate Iodide for Near-sightedness

Phase 4
Waitlist Available
Led By Stephen A Mathias, MD, MPH
Research Sponsored by Danbury Eye Physicians & Surgeons, PC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Refractive Errors
Secondary outcome measures
Axial Length
Choroiditis

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Echothiophate IodideExperimental Treatment1 Intervention
Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
Group II: Carboxymethylcellulose Sodium (0.5%)Placebo Group1 Intervention
Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks

Find a Location

Who is running the clinical trial?

Danbury Eye Physicians & Surgeons, PCLead Sponsor
Stephen A Mathias, MD, MPHPrincipal InvestigatorDanbury Eye Physicians & Surgeons, PC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Apr 2025